688488 艾迪药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.440-2.008-13.407-6.545-9.893
总资产报酬率 ROA (%)1.180-1.033-7.810-4.472-8.032
投入资产回报率 ROIC (%)1.413-1.273-9.201-5.052-8.871

边际利润分析
销售毛利率 (%)65.48966.79254.93346.19542.901
营业利润率 (%)11.1596.686-39.364-22.376-58.175
息税前利润/营业总收入 (%)12.2925.334-36.632-19.843-58.139
净利润/营业总收入 (%)8.7931.124-33.230-18.492-50.812

收益指标分析
经营活动净收益/利润总额(%)84.461127.03678.84396.92891.603
价值变动净收益/利润总额(%)-11.27870.958-10.678-15.376-11.805
营业外收支净额/利润总额(%)-10.242-95.1340.9230.0400.218

偿债能力分析
流动比率 (X)1.6261.3241.3791.7752.419
速动比率 (X)1.1840.9580.9861.3991.949
资产负债率 (%)50.66543.88642.92335.55727.578
带息债务/全部投入资本 (%)42.44134.15031.14023.71913.326
股东权益/带息债务 (%)127.356181.812207.807305.446617.002
股东权益/负债合计 (%)91.423114.929122.234181.238262.608
利息保障倍数 (X)5.6642.796-11.822-7.805-356.435

营运能力分析
应收账款周转天数 (天)79.13172.723138.534129.628126.837
存货周转天数 (天)378.926387.756420.481277.339349.064